- Previous Close
0.0112 - Open
0.0107 - Bid 0.0009 x --
- Ask 0.0308 x --
- Day's Range
0.0107 - 0.0107 - 52 Week Range
0.0001 - 0.0276 - Volume
109 - Avg. Volume
2,035 - Market Cap (intraday)
2.348M - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden.
www.lipigon.seRecent News: 9RP.F
View MorePerformance Overview: 9RP.F
Trailing total returns as of 3/14/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9RP.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9RP.F
View MoreValuation Measures
Market Cap
2.34M
Enterprise Value
1.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.42
Price/Book (mrq)
0.95
Enterprise Value/Revenue
1.70
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-246.49%
Return on Assets (ttm)
-59.89%
Return on Equity (ttm)
-107.35%
Revenue (ttm)
8.97M
Net Income Avi to Common (ttm)
-22.11M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
10.74M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-24.61M